09:52 AM EDT, 10/16/2024 (MT Newswires) -- Alnylam Pharmaceuticals ( ALNY ) said Wednesday that it has submitted a type 2 variation to the European Medicines Agency for vutrisiran, an investigational RNA interference therapy being developed to treat transthyretin amyloidosis with cardiomyopathy.

Vutrisiran is the generic name for Amvuttra, which has already received European Union's approval to treat hereditary transthyretin-mediated amyloidosis in adults with stage 1 or 2 polyneuropathy, the company said.

The company has submitted a supplemental new drug application to the US Food and Drug Administration for vutrisiran to treat ATTR amyloidosis with cardiomyopathy, the company said.

Price: 289.87, Change: +2.51, Percent Change: +0.87